Report: Gardasil cost-effective for girls, young women

Gardasil, Merck & Co.'s human papillomavirus vaccine designed to prevent cervical cancer, is cost-effective only for preadolescent girls and women as old as 21, according to an economic analysis by Harvard University researchers. The findings support the CDC's recommendation to routinely immunize 11- and 12-year-old girls before they become sexually active.

View Full Article in:

USA Today · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA